Illumina, Inc. (NASDAQ:ILMN) Receives $156.88 Average PT from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus rating of “Hold” from the nineteen ratings firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $156.8824.

A number of brokerages have commented on ILMN. Piper Sandler raised their price objective on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 1st. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, July 15th. JPMorgan Chase & Co. upgraded shares of Illumina from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Evercore restated an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Finally, Sanford C. Bernstein assumed coverage on shares of Illumina in a research note on Friday, June 26th. They issued a “market perform” rating and a $185.00 price objective on the stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Neutral Sentiment: Illumina was highlighted in a batch of valuation and relative-performance articles comparing it with peers such as Exelixis and Celldex Therapeutics, which may be keeping attention on whether ILMN looks cheap or expensive versus other healthcare names. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Analyst sentiment remained middling, with Illumina reported as having an average “Hold” recommendation, suggesting Wall Street is not seeing an immediate reason to aggressively buy or sell the shares. Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Coverage around Illumina’s role in the Billion Cell Atlas alliance and broader genomics/CRISPR collaboration was noted in commentary on AstraZeneca, but this appears more like a long-term strategic backdrop than a near-term stock mover. AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares outstanding for short positions, so there is no clear evidence here of a new bearish squeeze or panic selling signal.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $194.09 on Friday. The firm’s 50-day moving average price is $171.24 and its 200-day moving average price is $145.43. Illumina has a 1-year low of $88.00 and a 1-year high of $199.14. The firm has a market capitalization of $29.37 billion, a P/E ratio of 35.29, a P/E/G ratio of 2.87 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $0.97 EPS. The business’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts anticipate that Illumina will post 5.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several institutional investors have recently bought and sold shares of ILMN. WCM Investment Management LLC grew its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Invesco Ltd. lifted its position in shares of Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Morgan Stanley boosted its holdings in Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after purchasing an additional 1,005,474 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in Illumina during the first quarter worth about $106,462,000. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.